

II. AMENDMENTS TO THE CLAIMS

This listing of claims shall replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-37. (cancelled)

38. (currently amended) A method of effectively treating pain in humans, comprising orally administering to a human patient an oral dosage form comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting essentially of (i) N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof; and (ii) oxycodone and/or at least one pharmaceutically acceptable salt thereof.

39-46. (cancelled)

47. (previously presented) The method of claim 38, wherein the ratio of oxycodone and/or at least one pharmaceutically acceptable salt thereof to N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof is from about 0.001:1 to about 10:1.

48. (previously presented) The method of claim 38, wherein the oxycodone is present in the pharmaceutically acceptable salt form.

49. (previously presented) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

50. (previously presented) The method of claim 38, wherein the dosage form further comprises a sustained release carrier which provides a sustained release of the N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof.

51. (previously presented): The method of claim 38, wherein the N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 0.5 mg to about 1500 mg.

52. (previously presented) The method of any of claims 38, 47, 49, 50 or 51, wherein the analgesic compounds comprise oxycodone in an amount from 2.5 mg to 800 mg.